Buy this Israeli defense stock because of its 'battlefield tested tech,' Bank of America says

Bank of America reiterated a buy on Elbit Systems and raised its 12-month price target to $1,075, implying nearly 16% upside from Thursday's close. The bank sees land technology revenue growth of 30% in 2026 and ISR/electronic warfare growth of 15%, supported by demand for munitions replenishment and high-power laser technologies. Elbit has already soared 60% in 2026, trades above 60x forward earnings, and recently crossed $1,000 per share.

Analysis

The key underappreciated point is that Elbit is no longer being treated as a simple beneficiary of elevated defense budgets; it is being priced as a scarce, vertically integrated “picks-and-shovels” platform for battlefield autonomy, munitions replenishment, and electronic warfare. That matters because the market will likely keep awarding a premium as long as the secular rearmament cycle remains intact and Elbit continues to convert R&D into bankable product cycles faster than legacy primes. The second-order winner is likely not just Elbit itself but also Israeli and allied subcontractors tied to sensors, guidance, optics, and specialized electronics, where capacity constraints can sustain pricing power even if headline procurement growth normalizes.

The near-term risk is not demand—it's multiple compression. At >60x forward earnings, the stock is now trading as a hybrid defense/technology compounder, so any sign of margin dilution, order timing slippage, or a pause in geopolitical urgency could trigger a sharp de-rating even if fundamentals remain solid. The time horizon matters: in the next 1-3 months, the tape is more likely driven by momentum, analyst revisions, and investor FOMO; over 6-12 months, the key catalyst is whether backlog converts into free cash flow faster than capex and M&A consume it.

The consensus appears to be missing how dependent the bull case is on sustained narrative scarcity. If more investors start underwriting Elbit as a “default” defense-tech beta, the multiple premium could become self-limiting unless there is continued evidence of accelerating growth in the high-value electronic warfare / laser / ISR stack. Conversely, if peers with lower multiples begin to show similar growth, the relative-value case weakens and the stock becomes more vulnerable to profit-taking than to fundamental disappointment.

Key Decisions for Investors

• Stay long ESLT tactically on pullbacks over the next 2-4 weeks, but size it as a momentum trade rather than a core value position; the setup still favors upside, but risk/reward is getting thinner above 60x forward earnings.
• For a cleaner relative-value expression, pair long ESLT / short a slower-growing large-cap defense prime for the next 3-6 months; the trade works if investors continue paying up for defense-tech scarcity, but should be cut if peer growth catches up.
• Buy downside protection via 1-3 month put spreads on ESLT rather than outright shorting; this captures the main risk of multiple compression after any weak order or margin print while limiting carry in a crowded name.
• Add to a basket of suppliers to Elbit’s ecosystem on any weakness over the next 1-2 months; second-order beneficiaries should offer better risk/reward than chasing ESLT at elevated multiples.
• If ESLT re-tests recent highs without a fresh catalyst, trim 25-33% of the position and roll into a call spread to keep upside exposure while monetizing the premium re-rating.